The Billion Dollar Bromeliad?

I enjoy a bit of pork and I enjoy a bit of pineapple. I even don’t mind ’em together. So at first blush Anatara Life Sciences (ASX : ANR) is a company I should love. Also notwithstanding my personal regret that there is no possibility of covering Solagran on this site, it may surprise the reader to know that I actually quite like businesses based on natural products and nutriceuticals, especially if they genuinely work or experience some sort of unique market demand. If there is a proprietary process and the raw material chain has some degree of captivity, even better.

Anatara, however, bewilders me. This company has basically dusted off an old animal animal health product (field trials circa 1991) based on processed pineapple stems – the “Detach” product. The pineapple is actually a form of fruiting bromeliad and the proteases (enzymes) that are abundant in pineapple are purported to have a variety of medicinal and culinary uses. I must confess that I had seen “bromelain” in nutritional supplements before but didn’t realise it came from pineapples. Cool stuff! These enzymes, incidentally, are perfectly safe and is generally recongnised as such by the regulatory authourities (i.e. TGA’s ARTG).

This is unsurprising, it is basically er… pineapple.

But just because it is a natural product, doesn’t mean that it is devoid of medicinal value. Apparently lifestock, like humans, get the trots (known as “scour”). Pigs in particular. Give those piggies a little bromelain (a.k.a. “Detach”) and the scour goes away, and they are happy little campers again. The use of antibiotics in rearing lifestock is a major issue, and so any non-antibiotic alternatives that are reasonably proven to deliver a benefit is probably a good business (and anything to do with pork is good business, demand is phenomenal). Especially since we increasingly tend to want to buy meat products that are not treated with antibiotics and while the demand for antibiotic-free pork is still nascent, it is growing pretty fast. That demand is partially driven by growing consumer awareness of the potential risks of antibiotics in our food chain (irrespective of whether there is evidence that it is damaging to human health, though there have been significant concerns for at least a couple of decades), but also pressure to see animal husbandry practices that are more humane. If you want to raise pork without antibiotics, the first step is to basically dispense with ultra high-density farming practices.

As such, I would argue Anatara’s product sits at an interesting intersection between the constant need for improved farming productivity, concerns over animal health and welfare, and a growing consumer trend. The question is, with so many companies capable of producing food-grade bromelain, does Anatara have something that nobody else has? Notwithstanding that it is my general belief that Australian-made agricultural products come with the implied quality guarantee of a cleaner water/food chain than most of the world, it’s hard to see that something like product purity is a compelling differentiation to a farmer in China who is trying to maximise the yield/return equation, and where any type of feedstock cost is extremely price sensitive. With countries like China and Brazil being both top pork and pineapple producers, it’s hard to see that Anatara even has a relevant geographic nexus. Indeed, a quick look on Alibaba shows that there are plenty of Chinese manufacturers making products that look and feel like “Detach”. So, quite frankly, I don’t see the investment thesis.

I also don’t see the investment thesis to spend shareholder capital on validating the same therapeutic concept in humans. Contrary to the claims on Anatara’s website that there is no “effective prevention and treatment” for diarrhea (hey wait, what about Travelan!) it is relatively difficult to pre-empt diarrhea. This is because there are MANY things that can cause diarrhea and although E. coli is the common culprit for “traveller’s diarrhea” prophylaxis still isn’t straightforward. As for treating diarrhea, anyone who has been stuck with a nasty case of the shits whilst on vacation in Thailand will pretty much swear by loperamide (Immodium) as a life-saver. I speak from personal experience. Treating pigs for scour is one thing, treating humans for the trots, is probably a different matter. And again, if Anatara is successful in showing that it works well in people, the likely result would just be the emergence of a competing product that contains both bromelain and loperamide (one can already imagine the packaging with a little yellow tinge to it … “Immodium Pineapple for extra relief”).

Perhaps that is even Anatara’s opportunity?

Fundamentally, however, this is an opportunity that Anatara basically can’t capture exclusively for itself. So what’s the point in investing in it?

14 thoughts on “The Billion Dollar Bromeliad?

  1. I know the entrepreneur and lost money the first time she took this idea to ipo probably 7 years ago -‘- it was bundled with some ip from peter mac. She mortgaged the house to pay the patent attorney. The peter mac ip was no good and she ran out of money. She’s very passionate but I’m not sure about the business model.

    MV

    Like

  2. Is this anything to do with the ex-IVX assets? They just disappeared one day. The mystical magic powers of Mr. Bridges at work again.

    Like

  3. All rise. The court of public opinion is now in session.

    Case 17/07: ASX Life Sciences v. Antimicrobials in intensively reared animals.

    The plaintiff has tabled evidence for the courts consideration;

    Exhibit A: Chemeq Ltd
    Exhibit B: Imugene Ltd

    Defense counsel?

    Like

  4. So wait! If I get it right the assets of ANR are the same assets that came out of IVX. Assets that were stripped out of IVX under the stewardship of Mr. Bridges and with some kind of retainer held by HOG. HOG being the new entity that emerged from IVX.

    But how can that be?

    If the retainer was held by HOG then they must now hold some of the new ANR. Surely? Or what about ANR, stating that their assets were a rehashed version of IVX. If that isn’t in the prospectus then doesn’t that amount to some kind of dishonesty or misleading statement?

    For Chrissakes, why would anyone invest in biotech if its this crooked and nasty?

    Like

  5. Pingback: Novogen’s Graham Kelly : Jumped or Pushed? | The Long Tail

  6. Pingback: Anatara : No “Captnludd”, you’re the “shitwit” | The Long Tail

  7. Pingback: Twenty Questions for Phosphagenics | The Long Tail

Say something useful (or at least interesting)...

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s